Keefe Bruyette raises CBOE Holdings stock price target on derivatives strength

CFTC approved perpetual futures tied to individual stocks for trading on US exchanges. Chairman Michael Selig stated the contracts are approved under Commission Regulation 40.3. The Capital Markets Alliance, including Cboe, Citadel Securities, and others, filed a lawsuit challenging the approval, arguing the contracts fall under SEC jurisdiction and alleging procedural violations. Cboe's CEO Craig Donohue stated the approvals threaten investor protection and market integrity.

Cboe and Citadel Securities sued the CFTC to block stock perpetual futures, hours after the regulator approved them. The lawsuit aims to prevent US exchanges from offering these products, which are popular on Hyperliquid's platform. Hyperliquid's HYPE token saw volatility but remains up 2.8% in 24 hours. The outcome could impact Hyperliquid's US market expansion and competitors like Coinbase and Kalshi.

Cboe joined the Capital Markets Alliance (CMA) in suing to overturn the CFTC's approval of single-stock perpetual contracts. The case seeks to classify these derivatives as security-based swaps and block the approval. The CFTC allowed trading to begin on Nov. 3, while Cboe's CEO argues they should be regulated under U.S. securities laws. The case involves Coinbase, Kalshi, and Bitnomial.

Capital Markets Alliance, backed by Cboe (CBOE), Citadel Securities, and others, sued the CFTC to overturn its approval of stock perpetual futures, arguing they are securities-based swaps under SEC authority. The CFTC claims the policy extends perpetual futures to traditional securities. Cboe shares fell 0.90% on the news.

The Capital Markets Alliance, including Cboe Global Markets and Citadel Securities, sued the CFTC to overturn its approval of perpetual derivatives on individual U.S. stocks. The group argues these products are security-based swaps under the SEC's jurisdiction, not the CFTC's. They seek to vacate the approvals and bar the CFTC from enforcing them.

Cboe Global Markets (C67.DE) joined a legal action against the CFTC's approval of perpetual derivatives on U.S. stocks and ETFs, seeking injunctive relief. Cboe argues these products should be traded on registered securities platforms with investor protections. CFTC Chairman Michael S. Selig supports the approval for risk management and price discovery. The dispute centers on whether these contracts are security futures or swaps, with Cboe favoring SEC jurisdiction.